Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.37 |
| ▸ | GPR84 | Q9NQS5 | 6/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | FDPS | P14324 | 2/20 | 0.34 |
| ▸ | NAAA | Q02083 | 1/20 | 0.34 |
| ▸ | DGKA | P23743 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4408415 | 1.00 | L3MBTL1 (0.50) | L3MBTL1MAPTMAPK1NPSR1ALDH1A1 | |
| SCHEMBL8468455 | 0.85 | L3MBTL1 (0.47) | L3MBTL1MAPTMAPK1NPSR1ALDH1A1 | |
| SCHEMBL10388546 | 0.85 | MAPT (0.41) | L3MBTL1MAPTMAPK1NPSR1ALDH1A1 | |
| SCHEMBL4403990 | 0.81 | SLC6A4 (0.44) | L3MBTL1MAPTMAPK1NPSR1ALDH1A1 | |
| SCHEMBL3896866 | 0.80 | MAPK1 (0.46) | L3MBTL1MAPTMAPK1NPSR1ALDH1A1 | |
| SCHEMBL854811 | 0.79 | MAPT (0.53) | L3MBTL1MAPTMAPK1NPSR1ALDH1A1 | |
| SCHEMBL12469943 | 0.77 | FDPS (0.39) | L3MBTL1MAPTMAPK1NPSR1MEN1 | |
| SCHEMBL15670951 | 0.77 | FDPS (0.39) | L3MBTL1MAPTMAPK1NPSR1MEN1 | |
| SCHEMBL2228223 | 0.77 | FDPS (0.39) | L3MBTL1MAPTMAPK1NPSR1MEN1 | |
| SCHEMBL14127423 | 0.77 | FDPS (0.39) | L3MBTL1MAPTMAPK1NPSR1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8877958-B2 | Method to prepare beta-functionalized aliphatic esters | COGNIS IP MANAGEMENT GMBH (DE) | 2014-11-04 | — | — | US | disclosed |
| US-8877958-B2 | Method to prepare beta-functionalized aliphatic esters | COGNIS IP MANAGEMENT GMBH (DE) | 2014-11-04 | — | — | US | disclosed |
| US-20130225852-A1 | Method To Prepare beta-Functionalized Aliphatic Esters | COGNIS IP MANAGEMENT GMBH (DE) | 2013-08-29 | — | — | US | disclosed |
| US-20130225852-A1 | Method To Prepare beta-Functionalized Aliphatic Esters | COGNIS IP MANAGEMENT GMBH (DE) | 2013-08-29 | — | — | US | disclosed |
| WO-2012055455-A1 | A METHOD TO PREPARE BETA - FUNCTIONALIZED ALIPHATIC ESTERS | COGNIS IP MANAGEMENT GMBH (DE) | 2012-05-03 | — | — | WO | disclosed |
| EP-2447245-A1 | A method to prepare beta-functionalized aliphatic esters | Cognis IP Management GmbH (DE) | 2012-05-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225852-A1 | Method To Prepare beta-Functionalized Aliphatic Esters | CYP8B1, EBP, DBH | L3MBTL1 3996/4885MAPT 3724/4885MAPK1 2085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.